Alice Gottlieb, M.D., Ph.D.

Her pioneering work in immunobiologic therapies has significantly advanced the treatment of psoriasis and psoriatic arthritis. Notably, she conducted the first randomized controlled trial demonstrating the efficacy of TNF blockers as monotherapy for moderate to severe psoriasis, leading to FDA approval of multiple biologics that have transformed patient care. Dr. Gottlieb has authored over 400 peer-reviewed publications and has presented her research at more than 300 national and international conferences.

Prior to joining UT Southwestern, Dr. Gottlieb held leadership positions at institutions including Tufts Medical Center and the Icahn School of Medicine at Mount Sinai. She is a former member of the Board of Directors of the American Academy of Dermatology and serves on the boards of several international dermatology organizations. As Director of Clinical Trials at UT Southwestern, she leads the expansion of the department’s research infrastructure and fosters interdisciplinary collaboration across dermatologic and immunologic specialties.

Education:

• April, 1990-, March, 1993 Dermatology Residency (Academic Track), New York Hospital, NY, NY
• July, 1982-June, 1984 Rheumatic Diseases Fellow, The Hospital for Special Surgery, New York, NY
• June, 1980-June, 1982 Medical Resident, The New York Hospital, New York, NY
• July, 1973-, June 1980 The Rockefeller University/ Cornell University Medical College-MD-PhD Program, NY, NY. I was in the first class that accepted women into this program.
• 1979 Ph.D. in Immunology with Dr. Henry Kunkel at The Rockefeller University, NY, NY
• 1980 M.D. Cornell University Medical College, NY, NY
• Sept., 1969-June,1973 B.A. Brandeis University, Summa Cum Laude with Honors in Chemistry, Phi Beta Kappa; (Junior Year at the University of California at Santa Cruz)